Severe Dual Antiplatelet Dysfunction with High Perioperative Bleeding Risk
This TEG Platelet Mapping profile demonstrates severe platelet dysfunction from both P2Y12 inhibitor (83% ADP inhibition) and aspirin/NSAID therapy (96% AA inhibition), indicating a critically elevated risk of perioperative bleeding that mandates delaying elective surgery until platelet function recovers.
Key Findings
Your patient has profound impairment across both major antiplatelet pathways:
- ADP pathway: MA of 18 mm (normal 45-69) with 83% inhibition indicates active P2Y12 inhibitor effect (clopidogrel, ticagrelor, or prasugrel)
- Arachidonic acid pathway: MA of 11 mm (normal 51-71) with 96% inhibition indicates aspirin or NSAID effect
- Overall clot strength: Normal HKH-MA of 61 mm shows adequate fibrinogen and overall hemostatic capacity when platelets aren't inhibited
Clinical Implications for Bleeding Risk
The degree of platelet inhibition documented here directly predicts increased perioperative bleeding. Studies using TEG Platelet Mapping in cardiac surgery demonstrate that patients in the upper tertile of platelet dysfunction (like your patient) have significantly increased blood loss and transfusion requirements 1. Specifically, ADP inhibition >86% and ADP-MA <32 predict bleeding events with high sensitivity and specificity 2, 3.
Your patient exceeds both thresholds with 83% inhibition and MA of 18 mm—well below the cardiac surgery target of ADP-MA >50 mm mentioned in the lab comment.
Recommended Management Algorithm
For Elective Surgery:
Discontinue antiplatelet agents immediately:
Retest with TEG Platelet Mapping in 3-5 days as recommended in the lab comment 1
Proceed to surgery only when:
For Urgent/Semi-Urgent Surgery:
If surgery cannot be delayed, recognize this patient requires:
- Platelet transfusion to dilute dysfunctional platelets with functional ones [@2@, @4@]
- Higher transfusion thresholds than standard protocols [@14@, 5]
- Close monitoring for bleeding complications
- Possible use of desmopressin or other hemostatic agents
Critical Pitfalls to Avoid
Do not proceed with elective high-bleeding-risk surgery based solely on time since last antiplatelet dose. The French perioperative guidelines emphasize significant interindividual variability in platelet recovery [@2@, 1, @4@]. Your patient demonstrates why: despite presumably stopping medications, they retain near-maximal inhibition of both pathways.
Do not assume standard washout periods are sufficient. While guidelines recommend 5-7 day discontinuation periods, 25% of patients retain significant platelet dysfunction beyond these timeframes [@5@, @7@]. TEG Platelet Mapping identifies these high-risk patients who need extended washout.
Do not ignore the dual pathway inhibition. Combined aspirin and P2Y12 inhibitor therapy creates substantially higher bleeding risk than either agent alone [@3@, 1, @10@]. Both pathways must normalize before high-risk procedures.
Evidence Quality and Nuances
The French Working Group on Perioperative Haemostasis (GIHP) guidelines [@1@, 1, @3@] provide the strongest framework, though they note TEG Platelet Mapping evidence comes primarily from cardiac surgery populations. The European societies issued only Grade IIb recommendations for platelet function testing due to limited data [@2@, @4@, 1]. However, multiple observational studies consistently show TEG-PM parameters predict bleeding and transfusion requirements [@13@, 6, @16@].
The practical value: TEG Platelet Mapping allows you to identify patients like yours who need extended antiplatelet washout periods, potentially preventing life-threatening bleeding complications while avoiding unnecessary surgical delays in patients who recover platelet function quickly [@2@, @4